Innovation
Prevention is the best medicine
We get ahead of disease together by preventing and treating it with innovation in vaccines and specialty medicines.
Investors
We announced our quarter 1 2024 results on Wednesday, May 1st.
Press releases
- GSK data at ASCO and EHA showcase latest research and innovation across the oncology portfolio
- Nucala (mepolizumab) approved by US FDA for use in adults with chronic obstructive pulmonary disease (COPD)
- GSK to acquire efimosfermin, a phase III-ready potential best-in-class specialty medicine to treat and prevent progression of steatotic liver disease (SLD)


Choose your path
By bringing outstanding people together in an inclusive environment to do work that matters, we can impact the world’s health.
GSK Global links
Visit our Global site for additional features